百奥泰(688177.SH)：与 Avalon Pharma 就BAT3306（帕博利珠单抗）注射液签署授权许可及生产、供货和商业化协议

Group 1 - The core point of the article is that Baiotai has signed a licensing and commercialization agreement with Avalon for its BAT3306 (Pabrolizumab) injection, granting Avalon exclusive commercialization rights in Saudi Arabia and the MENA region, with potential total payments up to $7 million [1] - The agreement includes an upfront payment of $2 million, milestone payments not exceeding $5 million, and a percentage of net sales as revenue sharing [1] Group 2 - BAT3306 (Pabrolizumab) is a humanized monoclonal antibody drug developed according to guidelines from NMPA, FDA, and EMA for biosimilars, functioning as an immune checkpoint inhibitor [2] - The drug specifically binds to the PD-1 receptor on lymphocytes, blocking its interaction with PD-L1 and PD-L2, thereby reactivating T cells against tumor cells for cancer treatment [2] - The company is conducting a multicenter, randomized, double-blind, parallel-controlled clinical study to evaluate the pharmacokinetics, immunogenicity, safety, and efficacy of BAT3306 compared to US-Ketruda® in patients with stage IB-IIIA non-small cell lung cancer [2]